A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults

NCT ID: NCT01676675

Last Updated: 2013-03-15

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2013-03-31

Brief Summary

Influenza is an acute respiratory infection caused by influenza virus with high incidence and serious complications even causing death. According to the announcement released by the World Health Organization (WHO), the number of global annual influenza case was 0.6 to 1.2 billion and 0.5 to 1 million people died. The emergence of a new subtype of influenza virus may cause an influenza pandemic with occurence once every 10 to 50 years which cause serious adverse consequences for human health and social welfare worldwide.

From 1997 to 2003，the H5N1 virus infection has increased highly and gradually spreaded to Europe, Africa and other countries and regions. High mortality caused by H5N1 virus has attracted the WHO and national government great attention. So it is meaningful to develop vaccine to provide effective antibody to reduce the number of infections.

The objective of this study is to evaluate the safety and preliminary immunogenicity of a whole virus inactivated influenza H5N1 vaccine.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

7.5μg/0.5ml in subjects(12-17 years old)

whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21

Group Type: EXPERIMENTAL

7.5μg /0.5ml

Intervention Type: BIOLOGICAL

whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval

15μg/0.5ml in subjects(12-17 years old)

whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21

Group Type: EXPERIMENTAL

15.0μg /0.5ml

Intervention Type: BIOLOGICAL

whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval

30μg/0.5ml in subjects(12-17 years old)

whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21

Group Type: EXPERIMENTAL

30.0μg /0.5ml

Intervention Type: BIOLOGICAL

whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval

7.5μg/0.5ml in subjects(18-60 years old)

whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21

Group Type: EXPERIMENTAL

7.5μg /0.5ml

Intervention Type: BIOLOGICAL

whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval

15μg/0.5ml in subjects(18-60 years old)

whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21

Group Type: EXPERIMENTAL

15.0μg /0.5ml

Intervention Type: BIOLOGICAL

whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval

30μg/0.5ml in subjects(18-60 years old)

whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21

Group Type: EXPERIMENTAL

30.0μg /0.5ml

Intervention Type: BIOLOGICAL

whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval

0/0.5ml in adolescents (12-17 years old)

0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21

Group Type: PLACEBO_COMPARATOR

0/0.5ml placebo

Intervention Type: BIOLOGICAL

0/0.5ml placebo, two doses, 21 days interval

0/0.5ml in adults(18-60 years old)

0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21

Group Type: PLACEBO_COMPARATOR

0/0.5ml placebo

Intervention Type: BIOLOGICAL

0/0.5ml placebo, two doses, 21 days interval

Interventions

7.5μg /0.5ml

whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval

Intervention Type: BIOLOGICAL

15.0μg /0.5ml

whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval

Intervention Type: BIOLOGICAL

30.0μg /0.5ml

whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval

Intervention Type: BIOLOGICAL

0/0.5ml placebo

0/0.5ml placebo, two doses, 21 days interval

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy subjects aged from 12 to 60 years old of normal intelligence;
• The subjects' guardians are able to understand and sign the informed consent;
• Subjects established as healthy after medical history questioning, physical examination and clinical decision;
• Subjects who can comply with the requirements of the clinical trial protocol;
• Subjects who have never received influenza H5N1 vaccine and other preventive products;
• Subjects with temperature ≤37°C on axillary setting.

Exclusion Criteria

• Women in pregnancy / lactation or plan to be pregnant during the study;
• The subject has a history of allergy or is allergic with any Ingredient of vaccine, such as egg, ovalbumin;
• Had serious adverse reactions in previous vaccination, such as allergies, hives, difficult breath, angioneurotic edema or abdominal pain;
• Autoimmune diseases or immune deficiency;
• Had asthma, over the past two years, the condition is unstable in need of emergency treatment, hospitalization and oral or intravenous corticosteroids;
• Diabete (type I or type II) not including gestational diabete;
• Thyroidectomy history, or treatment because of thyroid diseases in the past 12 months;
• Over the past 3 years, severe angioneurotic edema, or need treatment in the past 2 years;
• Severe hypertension and blood pressure is still more than 150/100 mmHg after drug maintenance therapy;
• coagulation abnormalities diagnosed by doctor (such as lack of coagulation factors, coagulation disorder diseases, platelet abnormality) or coagulation disorder;
• Malignancy, active or treated tumor without explicitly been cured, or the possibility of a recurrence during the study period;
• Epilepsy not including alcohol epilepsy of stop drinking in the first 3 years or the simplicity not requiring treatment in the past 3 years;
• Asplenia, functional asplenia, and any circumstances leading to asplenia or splenectomy;
• Guillain-Barre syndrome;
• Had immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray to treat allergic rhinitis and corticosteroid treatment of the acute uncomplicated dermatitis) within the past six months;
• Received immune globulin in three months before study;
• Received other experimental drugs in 30 days before study;
• Received live attenuated vaccine in 30 days before study;
• Receiving subunit or inactivated vaccines in 14days before study, such as pneumococcal vaccine or allergy treatment;
• In prevention or treatment of the anti-TB (antituberculosis) now;
• Had fever (axillary temperature ≥ 38.0℃) 3 days before vaccination or had any acute illness in the past five days requiring systemic antibiotics or antiviral therapy);
• The subject is unable to comply with the study requirements because of psychology, or had mental illness or dual-stage affective psychosis not well controlled within the past two years or had psychology in medication and suicidal tendency in the past five years;
• According to the researcher, contrary to the study protocol or effect signed informed consent due to a variety of medical, psychological, social conditions, occupational factors or other conditions.

• Had any vaccination-related Grade 3 or more adverse reactions in 72 hours after first vaccination;
• Had serious adverse reactions caused by the study vaccination.
• Acute infection;
• Any condition the investigator believed may affect the evaluation of the vaccine.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wuhan Institute of Biological Products Co., Ltd

INDUSTRY

Sponsor Role: collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Jiangsu Provincial Center for Diseases Control and Prevention

Nanjing, Jiangsu, China

Countries

China

Other Identifiers

JSVCT011

Identifier Type: -

Identifier Source: org_study_id